RARE — Ultragenyx Pharmaceutical Inc.

Is RARE overbought or oversold? Here is the current MarketMoodz read.

Healthcare · Biotechnology

Oversold As of August 19, 2026

Ultragenyx Pharmaceutical Inc. (RARE) currently reads Oversold on the MarketMoodz overbought/oversold meter, as of August 19, 2026. The Healthcare name (Biotechnology) last closed at $25.49. The rating moved from Overbought to Oversold on August 18, 2026.

See all oversold Healthcare stocks →

AI analysis

Ultragenyx Pharmaceutical Inc. (RARE) is a rare-disease–focused biopharma with a portfolio of clinical-stage and commercial assets and a gene-therapy platform that offers high upside from successful program milestones. Recent market rotation into growth/biologics names and sector tailwinds around biologics and CDMO demand provide a constructive backdrop for near-term sentiment and potential multiple expansion. Key strengths include specialized commercial experience and partnership optionality, while principal concerns are binary clinical/regulatory outcomes, reimbursement dynamics, and cash runway that may necessitate capital raising. Given these dynamics, the outlook is characterized by asymmetric upside tied to clinical and commercial execution, balanced by above-average sector-specific execution and financing risks.

Key factors

  • Focused rare-disease and gene therapy pipeline with multiple clinical-stage programs that can drive meaningful revenue upside on successful readouts or approvals
  • Established commercial footprint and experience in launching specialty rare-disease therapies, supporting near-term revenue stability relative to discovery-stage peers
  • Favorable market technicals and recent risk-on sentiment toward growth/biologics names that can support re-rating and near-term share price appreciation
  • Biologics and CDMO demand tailwinds in the sector that could improve manufacturing access and margin leverage for gene-therapy scale-up
  • Potential business development and partnership optionality that could de-risk programs or provide non-dilutive funding

Risks

  • Clinical trial failures or delayed readouts for lead programs, which would materially impact valuation and forward prospects
  • Regulatory uncertainty on approval pathways and potential label or post-approval requirements that could limit commercial opportunity
  • Payer and reimbursement headwinds or pricing pressure from insurers and PBMs that could constrain uptake of high-cost rare-disease therapies
  • High cash burn and the potential need to raise capital, which could dilute existing shareholders or signal operational stress
  • Manufacturing scale-up challenges for complex biologics/gene therapies that could delay supply or increase costs
  • Broader market volatility and geopolitical headlines that could reverse the current risk-on mood and compress biotech multiples

Latest MarketMoodz coverage

See today's live rating, score and targets

Members see the live hourly rating for RARE — the numeric AI score plus targets and entry zones — while this public page updates nightly.

Start the 14-day trial

This page is for informational purposes only and is not investment, financial, tax, or legal advice. Ratings and research outputs can be wrong, incomplete, or stale. Past performance does not guarantee future results. Always do your own research and consider consulting a qualified professional.